The tributes were warm for Werner Lanthaler when he stepped down as CEO as Evotec SE at the beginning of the year but a chill has descended at the German biotech amid concerns about alleged misconduct by the industry veteran in his buying and selling of company shares.
Share Dealings Of Ex-CEO Cast A Cloud Over Evotec
The German biotech has distanced itself from recently resigned head Werner Lanthaler who appears to have violated the rules regarding the buying and selling of stock.
More from Legal & IP
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.